Differential expression of telomerase activity in neuroendocrine lung tumours: Correlation with gene product immunophenotyping

Journal of Pathology

Volumn 201, Issue 1, 2003, Pages 127-133

  Zaffaroni, Nadia ^a   De Polo, Daniela ^a   Villa, Raffaella ^a   Della Porta, Chiara ^a   Collini, Paola ^a   Fabbri, Alessandra ^a   Pilotti, Silvana ^a   Daidone, Maria Grazia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Gene products; Immunocytochemistry; Neuroendocrine lung tumours; Telomerase

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; GENE PRODUCT; PROTEIN BCL 2; PROTEIN P53; STEM CELL FACTOR; TELOMERASE;

ARTICLE; CARCINOID; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; LUNG SMALL CELL CANCER; LUNG TUMOR; NEUROENDOCRINE TUMOR; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL;

CARCINOID TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL DIVISION; HUMANS; IMMUNOPHENOTYPING; LUNG NEOPLASMS; NEOPLASM PROTEINS; NEUROENDOCRINE TUMORS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 0141515536     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1401     Document Type: Article

References (35)

1. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science 1995; 269: 1236-1241.
2. Harrington L, Zhou W, McPhail T, et al. Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev 1997; 11: 3109-3115.
3. Hahn WC, Counter CM, Lundberg AS, Beijesbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400: 464-468.
4. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-791.
5. Kelland LR. Telomerase inhibitors: targeting the vulnerable end of cancer? Anticancer Drugs 2000; 11: 503-513.
6. Otto WE. Lung epithelial stem cells. J Pathol 2002; 197: 527-535.
7. Gould VE, Linnoila RI, Memoli VA, Warren WH. Biology of disease. Neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias and neoplasms. Lab Invest 1983; 49: 519-537.
8. Lequaglie C, Patriarca C, Cataldo I, Muscolino G, Preda F, Ravasi G. Prognosis of resected well-differentiated neuroendocrine carcinoma of the lung. Chest 1991; 100: 1053-1056.
9. Sampietro G, Tomasic G, Collini P, et al. Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis. Appl Immunohistochem Mol Morphol 2000; 8: 49-56.
10. Sturm N, Rossi G, Lantuejoul S, et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 2002; 33: 175-182.
11. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. PNAS 2001; 98: 13 790-13 795.
12. Ullmann R, Petzmann S, Klemen H, Fraire AE, Hasleton P, Popper HH. The position of pulmonary carcinoids within the spectrum of neuroendocrine tumors of the lung and other tissues. Genes Chromosomes Cancer 2002; 34: 78-85.
13. Skuladottir H, Hirsch FR, Hansen HH, Olsen JH. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 2002; 37: 127-135.
14. Gómez-Román JJ, Romero AF, Castro LS, Nieto EH, Fernández-Luna JL, Val-Bernal JF. Telomerase activity in pulmonary neuroendocrine tumors. Correlation with histologic subtype. Am J Surg Pathol 2000; 24: 417-421.
15. Sarvesvaran J, Going JJ, Milroy R, Kaye SB, Keith WN. Is small cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis 1999; 20: 1649-1651.
16. Binaschi M, Supino R, Gambetta RA, et al. MRP gene over-expression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance. Int J Cancer 1995; 62: 84-89.
17. Villa R, Zaffaroni N, Folini M, et al. Telomerase activity in benign and malignant breast lesions: a pilot prospective study on fine-needle aspirates. J Natl Cancer Inst 1998; 90: 537-539.
18. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
19. Bankfalvi A, Navabi H, Bier B, Bocker W, Jasani B, Schmid KW. Wet autoclave pre-treatment for antigen retrieval in diagnostic immunohistochemistry. J Pathol 1994; 174: 223-228.
20. Wright WE, Shay JW. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 1992; 27: 383-389.
21. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997; 277: 955-959.
22. Meyerson M, Counter CM, Eaton EN, et al. hEst2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997; 90: 785-795.
23. Kyo S, Kanaya T, Takakura M, Inoue M. Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues. Int J Cancer 1999; 80: 60-63.
24. Liu JP. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 1999; 13: 2091-2104.
25. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998; 58: 4168-4172.
26. Ulaner GA, Hu JF, Vu TH, Oruganti H, Giudice LC, Hoffman AR. Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. Int J Cancer 2000; 85: 330-335.
27. Villa R, Della Porta C, Folini M, Daidone MG, Zaffaroni N. Possible regulation of telomerase activity by transcription and alternative splicing of telomerase reverse transcriptase in human melanoma. J Invest Dermatol 2001; 116: 867-873.
28. Zaffaroni N, Della Porta C, Villa R, et al. Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumours and in adjacent mammary glandular tissues: implications for telomerase activity. J Pathol 2002; 198: 37-46.
29. Yi X, White DM, Aisner DL, Baur JA, Wright WE, Shay JW. An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia 2000; 2: 433-440.
30. Wu X, Kemp B, Amos CI, et al. Associations among telomerase activity, p53 protein overexpression, and genetic instability in lung cancer. Br J Cancer 1999; 80: 453-457.
31. Maniwa Y, Yoshimura M, Obayashi C, et al. Association of p53 gene mutation and telomerase activity in resectable non-small cell lung cancer. Chest 2001; 120: 589-594.
32. Xu D, Wang Q, Gruber A, et al. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 2000; 19: 5123-5133.
33. Mandal M, Kumar R. Bcl-2 modulates telomerase activity. J Biol Chem 1997; 272: 14 183-14 187.
34. Albanell J, Lonardo F, Rusch V, et al. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 1997; 89: 1609-1615.
35. Fujiwara M, Okayasu I, Takemura T, et al. Telomerase activity significantly correlates with chromosome alterations, cell differentiation, and proliferation in lung adenocarcinomas. Mod Pathol 2000; 13: 723-729.